Briakinumab (ABT-874) is a fully human monoclonal antibody that specifically targets and neutralizes the p40 subunit shared by the cytokines IL-12 and IL-23. This antibody's action inhibits the signaling pathways of both interleukin-12 (IL-12) and interleukin-23 (IL-23), which are crucial mediators in the inflammatory processes associated with autoimmune disorders. Briakinumab is utilized extensively in research focused on autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, providing valuable insights into the pathophysiology of these conditions and potential therapeutic approaches.
Briakinumab (ABT-874) is a fully human monoclonal antibody that specifically targets and neutralizes the p40 subunit shared by the cytokines IL-12 and IL-23. This antibody's action inhibits the signaling pathways of both interleukin-12 (IL-12) and interleukin-23 (IL-23), which are crucial mediators in the inflammatory processes associated with autoimmune disorders. Briakinumab is utilized extensively in research focused on autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, providing valuable insights into the pathophysiology of these conditions and potential therapeutic approaches.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
